All In Biotech

Drug Trial Radar · NCT07389057

Assessing the Feasibility of Combining Dihydroartemisinin Piperaquine and Primaquine for Malaria Mass Drug Administration in High Endemic Communities in the Eastern Region of Ghana

Implementation Research to Assessing the Feasibility of Combining Dihydroartemisinin Piperaquine and Primaquine for Malaria Mass Drug Administration in High Endemic Communities in the Eastern Region of Ghana

Last checked: Nov 20, 2026Latest source record: Feb 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 9,000 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

9,000

Planned (sponsor's estimate)

Start

Nov 1, 2023

Primary completion

Nov 30, 2026

Study completion Nov 30, 2026

Sponsor

Lead sponsor
Noguchi Memorial Institute for Medical ResearchAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Medical Research Center Unit The Gambia (MRCG)
First posted
Feb 5, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 3 months
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Previous malaria control studies in Ghana have shown that community-wide approaches can substantially reduce malaria infections. In a mass testing, treatment and tracking (MTTT) study, more than 75% of people in target communities were reached, leading to a 24% reduction in asymptomatic malaria after one year. However, rapid diagnostic tests (RDTs) can miss very low-level infections, meaning some infected individuals are not treated and can continue to spread malaria. A pilot malaria mass drug administration (MDA) study using artemether-lumefantrine (AL) in the Eastern Region of Ghana showed a very large reduction (over 95%) in parasite carriage after repeated rounds of treatment. Despite this success, malaria infections later fluctuated, possibly because some parasites remained in mosquitoes and because mature gametocytes-the parasite stage responsible for transmission-are not fully eliminated by standard malaria medicines. To better interrupt malaria transmission, this study will use MDA with dihydroartemisinin-piperaquine (DHAP) combined with a single low dose of primaquine (PQ), which targets these transmission stages. The intervention will be given to the whole community every two months (six times per year) and compared with the current standard malaria control measures. The study will examine whether this approach reduces malaria parasite carriage, whether malaria returns after treatment stops, and whether repeated MDA affects malaria drug resistance markers in the population. This two-year implementation research will generate practical evidence to guide national malaria policy in Ghana and inform the potential use of MDA in other malaria-endemic African countries.

Conditions

  • Malaria Asymptomatic Parasitaemia
  • Malaria Falciparum
  • Malaria Infection
  • Malaria Transmission

Interventions

  • DHAPDrug

    A full 3-day course of oral DHAP will be based on weight and/or age taken once daily.

  • Single low dose PQDrug

    One dose of PQ on day 3

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Effect of DHAP and DHAP+PQ on the prevalence of malaria infection following MDATime frame: Time Frame: From enrolment of participants to end of treatment every two months over 24 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Pokrom sub district

    Accra, Eastern Region, Ghana · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.